CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-12-13 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +250,000 | 250,000 | ||
| 2023-12-13 | Wilson Mark Andrew Chief Legal Officer | Grant or award · Stock Option | +325,000 | 325,000 | ||
| 2023-12-13 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +1,300,000 | 1,300,000 | ||
| 2023-11-17 | Zalevsky Jonathan Chief R&D Officer | Sale | −9,646 | $0.49 | $5K | 274,039 |
| 2023-11-17 | Wilson Mark Andrew Chief Legal Officer | Sale | −7,179 | $0.49 | $4K | 243,780 |
| 2023-11-17 | ROBIN HOWARD W President & CEO | Sale | −19,877 | $0.49 | $10K | 899,922 |
| 2023-09-19 | GREER R SCOTT Director | Grant or award · Stock Option | +85,000 | 85,000 | ||
| 2023-09-19 | WHITFIELD ROY A Director | Grant or award · Stock Option | +85,000 | 85,000 | ||
| 2023-09-19 | Curet Myriam Director | Grant or award · Stock Option | +85,000 | 85,000 | ||
| 2023-09-19 | CHESS ROBERT Director | Grant or award · Stock Option 10b5-1 | +85,000 | 85,000 | ||
| 2023-09-19 | Brainard Diana Director | Grant or award · Stock Option | +85,000 | 85,000 | ||
| 2023-09-19 | Ajer Jeffrey Robert Director | Grant or award · Stock Option | +85,000 | 85,000 | ||
| 2023-09-18 | Curet Myriam Director | Sale | −4,359 | $0.69 | $3K | 27,418 |
| 2023-09-18 | Ajer Jeffrey Robert Director | Sale | −4,359 | $0.69 | $3K | 34,153 |
| 2023-08-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −9,703 | $0.78 | $8K | 283,685 |
| 2023-08-16 | Wilson Mark Andrew Chief Legal Officer | Sale | −7,221 | $0.78 | $6K | 250,959 |
| 2023-08-16 | ROBIN HOWARD W President & CEO | Sale | −19,998 | $0.78 | $16K | 919,799 |
| 2023-06-14 | WHITFIELD ROY A Director | Sale 10b5-1 | −30,000 | $0.57 | $17K | 216,250 |
| 2023-05-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −9,791 | $0.72 | $7K | 293,388 |
| 2023-05-16 | Wilson Mark Andrew Chief Legal Officer | Sale | −7,543 | $0.72 | $5K | 257,680 |
Page 6 of 18 · 355 trades